We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adicet Bio Inc | NASDAQ:ACET | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.34 | 1.28 | 1.36 | 1 | 09:07:59 |
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congress being held in Madrid, Spain from June 13-16, 2024.
Details of the poster presentation are as follows:
Title: ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T Cell Therapy Designed for Multiple Solid and Hematological Cancer Indications Presenting Author: Yvan Chanthery, Ph.D. Date & Time: June 14, 2024 at 18:00 CEST
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514346504/en/
Adicet Bio., Inc. Investor and Media Contacts
Anne Bowdidge abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200 janhavi.mohite@sternir.com
1 Year Adicet Bio Chart |
1 Month Adicet Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions